This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Daiichi Sankyo Co., Ltd.
Drug Names(s): SUN 4936h, HANP Injection 1000, recombinant alfa-human atrial natriuretic peptide
Description: Carperitide is a recombinant alfa-human atrial natriuretic peptide, a naturally occurring hormone in the body that aids in the healthy functioning of the heart. ANP is released in response to atrial stretch, and will cause vasorelaxation, inhibition of aldosterone secretion in the adrenal cortex, and inhibition of renin secretion in the kidney. ANP causes natriuresis (excretion of sodium in the urine) and a reduction in intravascular volume. The natriuretic effect results from a direct inhibition of sodium absorption in the renal collecting duct, increased glomerular filtration (filtering of the blood to form urine) and inhibited aldosterone production and secretion.
Deal Structure: In June 2003, Daiichi Suntory Pharma Co and Fujisawa Healthcare (now Astellas Pharma) executed a license agreement for carperitide. Fujisawa Healthcare acquired exclusive rights to develop, manufacture and market carperitide in North America and EU countries. Daiichi Pharmaceutical markets the product as HANP Injection 1000 in Japan.
In January 2007, Astellas announced that its US affiliate has terminated its license agreement with Daiichi regarding North American and European Union rights to carperitide for the treatment of acute heart failure.
Additional information available to subscribers only: